Blood-brain barrier company to-BBB moves into commercialization mode with new CEO Willem van Weperen
09-Feb-2009 -
Biopharma company to-BBB appointed Willem van Weperen as the new CEO. Willem van Weperen joins to-BBB after a long career at Genzyme, where he was involved in the development and commercialization of therapies in several European and Global leadership roles. These positions allowed him to be ...
brain tumors
diseases
encephalitis
+4